Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL.

Standard

Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL. / Carstens, Merwe; Bittner, Cordula; Krokowski, Manuela; Hadlak, Marco; Feller, Alfred C; Merz, Hartmut.

in: IN VIVO, Jahrgang 17, Nr. 4, 4, 2003, S. 359-363.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Carstens, M, Bittner, C, Krokowski, M, Hadlak, M, Feller, AC & Merz, H 2003, 'Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL.', IN VIVO, Jg. 17, Nr. 4, 4, S. 359-363. <http://www.ncbi.nlm.nih.gov/pubmed/12929591?dopt=Citation>

APA

Carstens, M., Bittner, C., Krokowski, M., Hadlak, M., Feller, A. C., & Merz, H. (2003). Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL. IN VIVO, 17(4), 359-363. [4]. http://www.ncbi.nlm.nih.gov/pubmed/12929591?dopt=Citation

Vancouver

Carstens M, Bittner C, Krokowski M, Hadlak M, Feller AC, Merz H. Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL. IN VIVO. 2003;17(4):359-363. 4.

Bibtex

@article{b086d366fe35416ea43f851450e726c4,
title = "Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL.",
abstract = "The use of whole cell vaccines to augment anti-tumour immunity has been explored throughout the last century. Using the recently established TS1G6 ALCL mouse model, we compared the ability of whole cell vaccines with different combinations of CpG oligodeoxynucleotides, Diphteria-, Pertussis- and Tetanus-vaccine (DPT) to enhance the immunogenicity of tumour cells. We have therefore developed a whole cell ELISA that detects the systemic anti-tumor-cell antibody response. CpG oligodeoxy-nucleotides can induce production of different TH1-cytokines and stimulate immune effector cells. Diphteria-, Pertusis- and Tetanusvaccine, injected together with irradiated tumor cells into Diphteria-, Pertussis- and Tetanus-preimmunized mice were used to serve as a target for the host's existing memory response and thus enhance the immunogenicity of the tumour cells by induction of a local inflammation. The combined application of oligodeoxynucleotides, the vaccines and irradiated tumor cells into preimmunized mice quickly induced very high titers of tumour cell-specific antibody response. We conclude that this therapy may be a new attractive part of a tumour immunization strategy.",
author = "Merwe Carstens and Cordula Bittner and Manuela Krokowski and Marco Hadlak and Feller, {Alfred C} and Hartmut Merz",
year = "2003",
language = "Deutsch",
volume = "17",
pages = "359--363",
journal = "IN VIVO",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "4",

}

RIS

TY - JOUR

T1 - Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL.

AU - Carstens, Merwe

AU - Bittner, Cordula

AU - Krokowski, Manuela

AU - Hadlak, Marco

AU - Feller, Alfred C

AU - Merz, Hartmut

PY - 2003

Y1 - 2003

N2 - The use of whole cell vaccines to augment anti-tumour immunity has been explored throughout the last century. Using the recently established TS1G6 ALCL mouse model, we compared the ability of whole cell vaccines with different combinations of CpG oligodeoxynucleotides, Diphteria-, Pertussis- and Tetanus-vaccine (DPT) to enhance the immunogenicity of tumour cells. We have therefore developed a whole cell ELISA that detects the systemic anti-tumor-cell antibody response. CpG oligodeoxy-nucleotides can induce production of different TH1-cytokines and stimulate immune effector cells. Diphteria-, Pertusis- and Tetanusvaccine, injected together with irradiated tumor cells into Diphteria-, Pertussis- and Tetanus-preimmunized mice were used to serve as a target for the host's existing memory response and thus enhance the immunogenicity of the tumour cells by induction of a local inflammation. The combined application of oligodeoxynucleotides, the vaccines and irradiated tumor cells into preimmunized mice quickly induced very high titers of tumour cell-specific antibody response. We conclude that this therapy may be a new attractive part of a tumour immunization strategy.

AB - The use of whole cell vaccines to augment anti-tumour immunity has been explored throughout the last century. Using the recently established TS1G6 ALCL mouse model, we compared the ability of whole cell vaccines with different combinations of CpG oligodeoxynucleotides, Diphteria-, Pertussis- and Tetanus-vaccine (DPT) to enhance the immunogenicity of tumour cells. We have therefore developed a whole cell ELISA that detects the systemic anti-tumor-cell antibody response. CpG oligodeoxy-nucleotides can induce production of different TH1-cytokines and stimulate immune effector cells. Diphteria-, Pertusis- and Tetanusvaccine, injected together with irradiated tumor cells into Diphteria-, Pertussis- and Tetanus-preimmunized mice were used to serve as a target for the host's existing memory response and thus enhance the immunogenicity of the tumour cells by induction of a local inflammation. The combined application of oligodeoxynucleotides, the vaccines and irradiated tumor cells into preimmunized mice quickly induced very high titers of tumour cell-specific antibody response. We conclude that this therapy may be a new attractive part of a tumour immunization strategy.

M3 - SCORING: Zeitschriftenaufsatz

VL - 17

SP - 359

EP - 363

JO - IN VIVO

JF - IN VIVO

SN - 0258-851X

IS - 4

M1 - 4

ER -